Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

IDH1 Is a Druggable Target in Acute Myeloid Leukemia

DOI: 10.1158/2159-8290.CD-RW2013-186 Published October 2013
  • Article
  • Info & Metrics
Loading
  • Major finding: Mutant IDH1 cooperates with HOXA9 to induce myeloproliferative disease/monocytic leukemia.

  • Approach: An in silico screen identified an inhibitor of mutant IDH1 that specifically killed primary AML cells.

  • Impact: Mutant IDH1 can promote leukemogenesis in mice and may be targetable in human AML.

Isocitrate dehydrogenase 1 (IDH1) mutations that result in the neomorphic conversion of α-ketoglutarate to R-2-hydroxyglutarate (R-2HG) are common in human acute myeloid leukemias (AML). Accumulation of R-2HG inhibits α-ketoglutarate–dependent enzymes such as DNA methyltransferases and histone demethylases, and expression of mutant IDH1 in mice has been associated with epigenetic alterations and hematopoietic progenitor cell expansion. However, it is not clear that mutant IDH1 has leukemogenic activity in vivo, as mutant IDH1 knock-in mice do not develop leukemia. Hypothesizing that mutant IDH1 might require cooperation with other oncogenes to induce leukemia, Chaturvedi and colleagues compared gene expression profiles of IDH1-mutant and IDH1–wild-type AML and noted that HOXA9 was the most overexpressed HOX gene in patients with IDH1-mutant AML. Expression of mutant IDH1 in Hoxa9-immortalized bone marrow cells dramatically decreased the survival of recipient mice, leading to a myeloproliferative-like disease with features of monocytic leukemia with a short latency. Mutant IDH1 expression promoted cell-cycle progression in association with increased MAPK signaling, but IDH1-mutant cells were refractory to inhibitors of this pathway. To identify mutant IDH1-selective inhibitors, the authors performed an in silico screen and found one compound predicted to bind the isocitrate-binding pocket of mutant IDH1. This compound, called HMS-101, specifically reduced intracellular R-2HG levels and viability of Hoxa9-immortalized cells expressing mutant IDH1. Moreover, HMS-101 induced apoptosis and prevented colony formation of bone marrow cells isolated from patients with IDH1-mutant AML, but not normal bone marrow cells isolated from healthy donors. Collectively, these findings establish that mutant IDH1 can cooperate with other oncogenes to drive leukemogenesis in vivo and suggest that mutant IDH1 may be safely and effectively targeted in AML.

Chaturvedi A, Cruz MM, Jyotsana N, Sharma A, Yun H, Görlich K, et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 2013 Aug 16 [Epub ahead of print].

  • ©2013 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 3 (10)
October 2013
Volume 3, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
IDH1 Is a Druggable Target in Acute Myeloid Leukemia
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
IDH1 Is a Druggable Target in Acute Myeloid Leukemia
Cancer Discov October 1 2013 (3) (10) OF24; DOI: 10.1158/2159-8290.CD-RW2013-186

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
IDH1 Is a Druggable Target in Acute Myeloid Leukemia
Cancer Discov October 1 2013 (3) (10) OF24; DOI: 10.1158/2159-8290.CD-RW2013-186
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Structures Identify Selpercatinib and Pralsetinib Resistance Mechanisms
  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
  • Deep Learning Algorithm Aids Breast Cancer Detection by Mammography
Show more Research Watch

Leukemia

  • IFITM3 Enhances PI3K Pathway Signaling to Promote B-cell Malignancies
  • The Oncogenes STAT5 and ERK Have Opposing Roles in Leukemogenesis
  • Preleukemic Cells Can Be Eliminated in NPM1-Mutant Acute Myeloid Leukemia Models
Show more Leukemia
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement